In an observational study, Mayo Clinic researchers report that the combination of casirivimab and imdevimab—two monoclonal antibody treatments under Food and Drug Administration emergency use authorization—keep high-risk patients out of the hospital when infected with mild to moderate COVID-19. The findings appear in The Lancet’s EClinicalMedicine. Nearly 1,400 Mayo Clinic patients were enrolled in the […]
Home »
FDA Authorizes Use of Monoclonal Antibody Treatment for COVID-19
MONDAY, Nov. 23, 2020 — A combination of two monoclonal antibodies was granted emergency use authorization (EUA) for the treatment of mild-to-moderate COVID-19, the U.S. Food and Drug Administration announced Saturday. The combination of casirivimab and imdevimab, which must be administered together by intravenous infusion, is approved for use in treating patients ages 12 years […]